About Us

Our mission is to empower people living with neuromuscular diseases to live longer, more independent lives.

Press Releases

Nov 6, 2016

Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
Oct 27, 2016

Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Oct 19, 2016

MDA and RYR-1 Foundation Partner to Advance Research and Care for RYR1-Related Myopathies
Sep 27, 2016

MDA and Target ALS Foundation Partner to Advance ALS Research and Therapy Development
Sep 25, 2016

Biogen Submits NDA for Nusinersen to Treat Spinal Muscular Atrophy
Sep 18, 2016

MDA Celebrates FDA Accelerated Approval of Eteplirsen for Treatment of Duchenne Muscular Dystrophy

« first
‹ previous
…
49
50
51
52
53
54
55
56
57
…
next ›
last »

Find MDA
in your Community